Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

LifeMD (LFMDP) Common Equity (2016 - 2025)

Historic Common Equity for LifeMD (LFMDP) over the last 14 years, with Q3 2025 value amounting to $3.4 million.

  • LifeMD's Common Equity rose 16607.66% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 16607.66%. This contributed to the annual value of -$9.1 million for FY2024, which is 31683.24% down from last year.
  • As of Q3 2025, LifeMD's Common Equity stood at $3.4 million, which was up 16607.66% from -$1.8 million recorded in Q2 2025.
  • In the past 5 years, LifeMD's Common Equity ranged from a high of $22.7 million in Q4 2021 and a low of -$18.7 million during Q3 2021
  • In the last 5 years, LifeMD's Common Equity had a median value of -$2.3 million in 2025 and averaged -$3.0 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 154184.31% in 2022, then crashed by 82612.2% in 2023.
  • Over the past 5 years, LifeMD's Common Equity (Quarter) stood at $22.7 million in 2021, then tumbled by 152.2% to -$11.9 million in 2022, then soared by 135.29% to $4.2 million in 2023, then crashed by 316.83% to -$9.1 million in 2024, then skyrocketed by 137.08% to $3.4 million in 2025.
  • Its Common Equity stands at $3.4 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$2.3 million for Q1 2025.